Literature DB >> 22772533

First therapy targeting Parkinson's proteins enters clinical trials.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22772533     DOI： 10.1038/nm0712-992b

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

2.  Set back to Alzheimer vaccine studies.

Authors:  Karen Birmingham; Simon Frantz
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

3.  Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

4.  Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.

Authors:  Eric J Benner; Rebecca Banerjee; Ashley D Reynolds; Simon Sherman; Vladimir M Pisarev; Vladislav Tsiperson; Craig Nemachek; Pawel Ciborowski; Serge Przedborski; R Lee Mosley; Howard E Gendelman
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.